Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56

Summary

Results of the EscaLating ClopidogrEl by InVolving A GeneTic StratEgy — Thrombolysis In Myocardial Infarction 56 [ELEVATE TIMI 56] trial showed that tripling the maintenance dose of clopidogrel in CYP2C19*2 heterozygote patients achieved levels of platelet reactivity that were similar to the standard-dose clopidogrel in noncarriers.

  • Myocardial Infarction Clinical Trials
  • Thrombotic Disorders Genomics
View Full Text
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Myocardial Infarction Clinical Trials
Thrombotic Disorders Genomics